[Opinion] CHMP clears path for GSK’s Blenrep relaunch, recommends four other drugs

Blenrep Gets European Nod to Treat Multiple Myeloma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for Blenrep (belantamab mafodotin) for the treatment of relapsed or refractory multiple myeloma.  The drug is an antibody drug conjugate comprising a humanized IgG1κ monoclonal antibody targeting the B-cell maturation antigen (BCMA), conjugated with a […] The post Blenrep Gets European Nod to Treat Multiple Myeloma first …

CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma - Pharmafile

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Blenrep (belantamab mafodotin) in combination with either bortezomib and dexamethasone (BVd) or pomalidomide plus dexamethasone (BPd) for the treatment of adults with relapsed/refractory multiple myeloma. The combinations are intended for patients who […] The post CHMP issues positive opinion for…

CHMP clears path for GSK’s Blenrep relaunch, recommends four other drugs

GSK, Roche and SpringWorks Therapeutics were among those that secured a positive opinion for new drugs from the European Medicines Agency’s human medicines committee (CHMP) on Friday. The agency gave the